Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
It's not often that a failed clinical trial leads to a scientific breakthrough. When patients in the UK started showing adverse side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back through the data and worked with patient samples to see what went wrong.
About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell growth, can also make the cancer vulnerable.
The current treatment of patients diagnosed with advanced or metastatic head and neck cancer (HNC) is ineffective.
In this interview, we speak to Kirill Kiselyov, Ph.D, and Umamaheswar Duvvuri, M.D, Ph.D, from the University of Pittsburgh, about their latest research into hydroxychloroquine, a drug widely used to prevent and treat malaria, as a potential treatment for head and neck cancers.
A new study suggests that the malaria drug hydroxychloroquine inhibits pathways that drive resistance to the chemotherapy agent cisplatin in head and neck cancers and restores tumor-killing effects of cisplatin in animal models.
A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.
A large, multi-institutional study demonstrates that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment.
A new study finds that an artificial intelligence (AI) model incorporating multiple methods of machine learning accurately detects thyroid cancer and predicts pathological and genomic outcomes through analysis of routine ultrasound images.
Patients undergoing primary radiotherapy treatment with or without chemotherapy, rather than surgery, for head and neck cancers are more likely to experience delays in their treatment starting, according to a new analysis from Flinders University.
The Wistar Institute announces the initiation of a Phase 2 clinical study of VK-2019 in patients with advanced Epstein-Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) and lymphoma.
Researchers at Mass Eye and Ear and Mass General Hospital have developed a blood test, or liquid biopsy, for head and neck cancer associated with the human papilloma virus (HPV) that was shown in a new study to be more accurate, faster and cheaper than conventional testing methods.
Immune checkpoint inhibitors are a type of cancer treatment that help the immune system's T cells recognize and attack tumors. But these immunotherapy drugs aren't effective against all cancers.
Two new studies revealed that anti-PD-1 immunotherapy given before surgery was safe and effective for patients with oral-cavity squamous cell carcinoma (OCSCC) and identified potential molecular biomarkers in the blood and tumors of patients that would show how likely it is that someone would respond to immunotherapy.
Armed with a novel strategy they developed for bolstering the body's immune response, scientists at Albert Einstein College of Medicine have successfully suppressed HIV infections in mice-;offering a path to a functional cure for HIV and other chronic viral infections.
Chinese Americans and Laotian Americans were over 10 and 14 times more likely to be diagnosed with nasopharyngeal cancer, respectively, than non-Hispanic white Americans, with incidence rates surpassing other Asian American subgroups, according to results presented at the virtual 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held October 6-8, 2021.
NYU Langone Health continues to broaden access to high-quality primary and specialty care with recent expansions in Long Island, Queens, Manhattan, and Brooklyn.
In three studies from the Cancer Cell Map Initiative, researchers uncovered previously unknown interactions between proteins that drive cancer and combined this new data to generate a map of protein pathways informing cancer outcomes.
Cancer immunotherapy seeks to turn "cold" tumors into "hot" tumors––those that respond to immunotherapy––by awakening and enlisting the body's own immune system.
Researchers at University of California San Diego and University of California San Francisco have mapped out how hundreds of mutations involved in two types of cancer affect the activity of discrete groups of proteins that are the ultimate actors behind the disease.
Blocking the PD-1 inhibitory pathway within a subset of specialized T-cells may improve overall immune response against virally driven cancers, according to findings published in Nature.